Add-on Fibrates’ Cardio Protection Still Evident Years On
The extended follow-up study (ACCORDION) of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, evaluated the ‘legacy effects’ of fibrate add-on therapy on mortality and major cardiovascular outcomes in patients with dyslipidaemia. Fibrate treatment during the initial trial period was associated with a legacy benefit of improved survival over a post-trial follow-up. This is a shortened version of the original article.
Modern Medicine – Issue 2 2023
